

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

TSCHOPE, et al.

Serial Number: 09/508,510

Filed: May 26, 2000

For: LIQUID INTERFERON-BETA FORMULATION



Attny. Dck. No. 100564-00002

Examiner: S. Prasad

Group Art Unit: 1646

RECEIVED
AUG 24 2001
AUG 20 2001
TECH CENTER 1600/2000 CENTER 1600/2900

STATEMENT UNDER 37 CFR §1.825

Assistant Commissioner of Patents
Washington, D.C. 20231

August 16, 2001


Sir:

In accordance with 37 C.F.R.1.825, applicants are submitting herewith a revised Sequence Listing for the above-identified application both in paper copy form and in computer readable form.

The name of the file on the computer readable form (CRF) is 56400002-sequence.txt. The paper copy and the computer readable form are the same. No new matter has been added, and consideration and entry of the paper copy and CRF is respectfully requested.

In the event that this paper is not considered to be timely filed, applicants hereby petition for an appropriate extension of time. The fee for any such extension may be charged to our Deposit Account No. 01-2300, along with any other fees with respect to this paper.

Respectfully submitted,
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC.


Lynn A. Bristol
Registration No. P-48,898

1050 Connecticut Avenue, N.W.,
Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

PTO COPY

Application No.: 09/508510

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

SEQUENCE LISTING



<110> Tschöpe, Michael;
Siklosi, Thomas;
Schroeder, Peter; and
Hofer, Hans.

<120> Liquid Interferon-BETA Formulations

<130> 17150P US WO (DR)

<140> U.S. 09/508,510

<141> 2000-05-26

<150> PCT/EP98/06065 and EP 97 116 562.6

<151> 1998-09-23 (PCT/EP98/06065) and 1997-09-23 (EP 97 116 562.6)

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> Homo sapiens

<400> 1

Glu Asp Phe Thr Arg Gly Lys

1

5

<210> 2

<211> 6

<212> PRT

<213> Homo sapiens

RECEIVED
AUG 24 2001
TECH CENTER 1600/2900

RECEIVED
AUG 20 2001
TECH CENTER 1600/2900

Sub B1

A1

<400> 2

Thr Val Leu Glu Glu Lys

1

5

<210> 3

<211> 7

<212> PRT

<213> Homo sapiens

<400> 3

Gln Leu Gln Gln Phe Gln Lys

1

5

<210> 4

<211> 8

<212> PRT

<213> Homo sapiens

<400> 4

Leu Xaa Ser Ser Leu His Leu Lys

1

5

<210> 5

<211> 8

<212> PRT

<213> Homo sapiens

<400> 5

Leu Met Ser Ser Leu His Leu Lys

1

5

<210> 6

<211> 12

<212> PRT

<213> Homo sapiens

<400> 6

Asp Arg Xaa Asn Phe Asp Ile Pro Glu Glu Ile Lys

1

5

10

<210> 7

<211> 11

<212> PRT

<213> Homo sapiens

<400> 7

Arg Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys

1

5

10

<210> 8

<211> 12

<212> PRT

<213> Homo sapiens

<400> 8

Asp Arg Met Asn Phe Asp Ile Pro Glu Glu Ile Lys

1

5

10

<210> 9

<211> 14

<212> PRT

<213> Homo sapiens

<400> 9

Leu Leu Trp Gln Leu Asn Gly Arg Leu Glu Tyr Cys Leu Lys

1

5

10

<210> 10

<211> 19

<212> PRT

<213> Homo sapiens

<400> 10

Xaa Ser Tyr Asn Leu Leu Gly Phe Leu Gln Arg Ser Ser Asn Phe Gln

1

5

10

15

Cys Gln Lys

<210> 11

<211> 19

<212> PRT

<213> Homo sapiens

<400> 11

Met Ser Tyr Asn Leu Leu Gly Phe Leu Gln Arg Ser Ser Asn Phe Gln

1

5

10

15

Cys Gln Lys

<210> 12

<211> 30

<212> PRT

<213> Homo sapiens

<400> 12

Glu Tyr Ser His Cys Ala Trp Thr Ile Val Arg Val Glu Ile Leu Arg

1

5

10

15

Asn Phe Tyr Phe Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn

20

25

30

<210> 13

<211> 47

<212> PRT

<213> Homo sapiens

<400> 13

Glu Asp Ala Ala Leu Thr Ile Tyr Glu Xaa Leu Gln Asn Ile Phe Ala

1

5

10

15

Ile Phe Arg Gln Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val

20

25

30

Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn His Leu Lys

35

40

45

<210> 14

<211> 47

<212> PRT

<213> Homo sapiens

<400> 14

Glu Asp Ala Ala Leu Thr Ile Tyr Glu Met Leu Gln Asn Ile Phe Ala

1

5

10

15

Ile Phe Arg Gln Asp Ser Ser Ser Thr Gly Trp Asn Glu Thr Ile Val

20

25

30

Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn His Leu Lys

35

40

45

sub
B₁

A